At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02617 TRANSTHERA-B
Not Yet Opened 04-09 16:08:11
71.250
-1.500
-2.06%
High73.700Low70.750Vol651.50K
Open73.300D1 Closing72.750Amplitude4.06%
Mkt Cap28.43BTradable Cap21.66BTotal Shares399.00M
T/O46.82MT/O Rate0.21%Tradable Shares304.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod
Bulletin Express  ·  04-07 19:45
TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod
TransThera proposes H-share award scheme for employee compensation
Reuters  ·  04-07 19:40
TransThera proposes H-share award scheme for employee compensation
TransThera Sciences files directors list with Hong Kong Stock Exchange
Reuters  ·  04-01
TransThera Sciences files directors list with Hong Kong Stock Exchange
TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan
Reuters  ·  04-01
TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan
TransThera proposes bylaw amendments shifting supervisory powers to board audit committee
Reuters  ·  04-01
TransThera proposes bylaw amendments shifting supervisory powers to board audit committee
Transthera FY25 net loss widens 8% to RMB 296 million
Reuters  ·  04-01
Transthera FY25 net loss widens 8% to RMB 296 million
TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns
Bulletin Express  ·  03-31
TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns
TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director
Stock News  ·  03-31
TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director
TransThera Sciences Widens Loss in 2025
MT Newswires Live  ·  03-31
TransThera Sciences Widens Loss in 2025
TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan
Stock News  ·  03-31
TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan
BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million
Reuters  ·  03-31
BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million
Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln
THOMSON REUTERS  ·  03-31
Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln
TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend
Bulletin Express  ·  03-19
TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend
TransThera Sciences to hold board meeting on annual results and final dividend
Reuters  ·  03-19
TransThera Sciences to hold board meeting on annual results and final dividend
Tencent Holdings Reports Annual Results with 16% Profit Growth and Final Dividend
Stock News  ·  03-19
Tencent Holdings Reports Annual Results with 16% Profit Growth and Final Dividend
TransThera Sciences Doses First Patient in Breast Cancer Drug Trial
MT Newswires Live  ·  03-18
TransThera Sciences Doses First Patient in Breast Cancer Drug Trial
TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer
Stock News  ·  03-18
TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer
TransThera doses first patient in China Phase II trial of tinengotinib plus fulvestrant for HR+/HER2- metastatic breast cancer
Reuters  ·  03-18
TransThera doses first patient in China Phase II trial of tinengotinib plus fulvestrant for HR+/HER2- metastatic breast cancer
Shares of Transthera Sciences Down 4%
THOMSON REUTERS  ·  03-11
Shares of Transthera Sciences Down 4%
TransThera Sciences Included as Constituent of Hang Seng Index Series
MT Newswires Live  ·  03-09
TransThera Sciences Included as Constituent of Hang Seng Index Series
No data available

Introduction

Company Name.
TRANSTHERA-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
Issue price:
--